Sustained efficacy and favorable safety profile with
remibrutinib in patients with chronic inducible
urticaria: 52-week results from the phase 3 remind
study
Ana M. Giménez-Arnau,
Luis F. Ensina,
Silvia M. Ferrucci,
Lindsey Finklea,
Atsushi Fukunaga,
Koremasa Hayama,
Michihiro Hide,
Johannes S. Kern,
Moisés Labrador-Horrillo,
Philip H. Li,
Giselle Mosnaim,
John Reed,
Heike Rockmann,
Sarbjit Saini,
Petra Staubach,
Sebastian Volc,
Jinhua Xu,
Bin Yang,
Alis Burciu,
Li Chen,
Clarice Field,
Sibylle Haemmerle,
Karine Lheritier,
Christine-Elke Ortmann,
Miriam Porter,
Wei Wang,
Martin Metz